Avelumab Plus Best Supportive Care Shows Efficacy in Urothelial Carcinoma
Petros Grivas, MD, PhD, discusses the JAVELIN Bladder 100 trial of maintenance avelumab plus best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in patients with advanced urothelial carcinoma.
Petros Grivas, MD, PhD, associate professor in the Division of Medical Oncology and clinical director of the Genitourinary Cancers Program at the University of Washington School of Medicine, discusses the JAVELIN Bladder 100 trial of maintenance avelumab (Bavencio) plus best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in patients with advanced urothelial carcinoma.
This phase 3 trial demonstrated a statistically and clinically significant difference with a prolongation of overall survival (OS) for patients receiving avelumab plus best supportive care compared with best supportive care alone. In patients with avelumab plus best supportive care, the median OS was over 21 months and about 14 months in patients with best supportive care alone, which is a big difference compared to what is usually seen in oncology, according to Grivas. He says this made more statistical rigor with an impressive hazard ratio of 0.69, which suggest patients getting avelumab plus best supportive care will live longer.
Grivas says patients do not need to be checked for any biomarkers in this setting, such as PD-L1, since the OS benefit was seen in all-comers.
<< View more resources and information regarding bladder cancer
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
